A Phase 2 interventional study of Azilsartan Medoxomil and Azilsartan Medoxomil in Hypertension, sponsored by Takeda. Completed at 54 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.
Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 13th largest by enrollment, is the only one that started in 2006, is the only one in phase 2, and was the 1st registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Gedeon Richter Plc. · Sites in Russian Federation
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
This study's enrollment of 449 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 566 across the 21 interventional studies. Of the 20 that completed or were terminated, 20 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 3 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
44 studies in Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 44 studies in Hypertension by Takeda, this one is the 15th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2006, is one of 4 in phase 2, and was the 1st registered.
Takeda’s Hypertension studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing azilsartan medoxomil in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 44 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. Data from the Framingham Heart study suggest that the lifetime risk of developing hypertension among 55- to 65-year-old individuals is greater than 90%. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of hypertension treatments, hypertension remains inadequately controlled; only about one third of patients continue to maintain control successfully. To help address these matters, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure proposes a more aggressive intervention to hypertension management with more potent antihypertensive agents and combination therapy.
Takeda Global Research \& Development Center, Inc. is developing TAK-491 (azilsartan medoxomil) to treat mild to moderate essential hypertension. Azilsartan medoxomil is a prodrug that is rapidly hydrolyzed to the activity moiety, azilsartan, which is an angiotensin II type 1 receptor antagonist. This study is proposed to evaluate the efficacy, safety and tolerability of multiple doses of azilsartan medoxomil at five dose levels in subjects with mild to moderate uncomplicated essential hypertension.
Individuals who want to participate in this study will be required to provide written informed consent. Study participation is anticipated to be about 11 weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, vital signs including sitting and standing blood pressure and pulse, body height and weight, physical examinations, electrocardiogram Outside of the study center, participants will be required to wear an ambulatory blood pressure monitoring device at approximately 24 and 36 hour intervals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Azilsartan Medoxomil
Drug: Azilsartan Medoxomil
Drug: Azilsartan Medoxomil
Drug: Azilsartan Medoxomil
Drug: Azilsartan Medoxomil
Drug: Olmesartan
Drug: Placebo
Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Also known as: TAK-491, Edarbi
Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Also known as: TAK-491, Edarbi
Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Also known as: TAK-491, Edarbi
Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Also known as: TAK-491, Edarbi
Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Also known as: TAK-491, Edarbi
Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Also known as: Benicar
Matching placebo tablets, orally, once daily for up to 8 weeks.
Change From Baseline in Sitting Clinic Diastolic Blood Pressure.
The change in sitting clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 8.
Change From Baseline in Sitting Clinic Systolic Blood Pressure.
The change in sitting clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 8
Change From Baseline in Standing Clinic Systolic Blood Pressure.
The change in standing clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough standing systolic blood pressure measurements.
Time frame: Baseline and Week 8.
Change From Baseline in Standing Clinic Diastolic Blood Pressure.
The change in standing clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough standing diastolic blood pressure measurements.
Time frame: Baseline and Week 8.
Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 10 to 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours.
Time frame: Baseline and Week 8.
Change From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 10 to 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours.
Time frame: Baseline and Week 8.
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in trough mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in trough mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 8.
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 8.
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 8.
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 8.
Change From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 24-36-hour mean systolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 24-36-hour mean diastolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 34-36-hour mean systolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
The change in the 34-36-hour mean diastolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing.
Time frame: Baseline and Week 8.
Participants enrolled at 76 investigative sites in Argentina, Mexico, Peru and the United States from 16 May 2006 to 07 December 2006.
| Milestone | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Started | 65 | 65 | 64 | 63 | 64 | 64 | 64 |
| Completed | 63 | 59 | 57 | 59 | 57 | 57 | 52 |
| Not completed | 2 | 6 | 7 | 4 | 7 | 7 | 12 |
| Withdrew: Adverse event | 0 | 1 | 1 | 1 | 2 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 | 1 | 0 | 1 | 3 | 4 |
| Withdrew: Lack of efficacy | 1 | 0 | 5 | 2 | 2 | 0 | 3 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Other | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
The change in sitting clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Sitting Clinic Diastolic Blood Pressure. | -10.8 ± 1.08 | -13.1 ± 1.08 | -11.5 ± 1.08 | -13.6 ± 1.10 | -11.6 ± 1.08 | -11.0 ± 1.08 | -7.9 ± 1.12 |
The change in sitting clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Sitting Clinic Systolic Blood Pressure. | -11.0 ± 1.66 | -15.7 ± 1.66 | -14.7 ± 1.66 | -17.1 ± 1.69 | -13.3 ± 1.66 | -13.5 ± 1.66 | -4.9 ± 1.73 |
The change in standing clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough standing systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Standing Clinic Systolic Blood Pressure. | -11.4 ± 1.78 | -13.4 ± 1.78 | -16.1 ± 1.78 | -14.6 ± 1.81 | -14.0 ± 1.79 | -11.4 ± 1.78 | -3.3 ± 1.85 |
The change in standing clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough standing diastolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Standing Clinic Diastolic Blood Pressure. | -9.2 ± 1.17 | -11.0 ± 1.18 | -10.2 ± 1.17 | -11.3 ± 1.19 | -11.2 ± 1.18 | -10.8 ± 1.17 | -6.9 ± 1.23 |
The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.5 ± 1.34 | -12.1 ± 1.49 | -11.1 ± 1.46 | -15.8 ± 1.57 | -12.4 ± 1.49 | -9.3 ± 1.42 | 1.0 ± 1.53 |
The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -4.2 ± 0.90 | -7.3 ± 1.01 | -7.5 ± 0.99 | -9.6 ± 1.06 | -8.2 ± 1.01 | -6.2 ± 0.96 | 1.2 ± 1.03 |
The change in the 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.2 ± 1.54 | -13.0 ± 1.72 | -11.8 ± 1.68 | -17.2 ± 1.80 | -13.0 ± 1.72 | -7.4 ± 1.63 | 0.6 ± 1.76 |
The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -3.6 ± 1.05 | -7.3 ± 1.18 | -8.0 ± 1.15 | -10.0 ± 1.23 | -8.7 ± 1.18 | -5.1 ± 1.12 | 0.6 ± 1.21 |
The change in the 10 to 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -8.0 ± 1.93 | -11.4 ± 2.14 | -12.2 ± 2.12 | -17.4 ± 2.24 | -13.7 ± 2.12 | -7.8 ± 2.03 | 0.1 ± 2.22 |
The change in the 10 to 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -3.8 ± 1.37 | -5.7 ± 1.52 | -7.4 ± 1.50 | -9.1 ± 1.59 | -8.8 ± 1.50 | -4.7 ± 1.44 | 0.5 ± 1.58 |
The change in trough mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -10.9 ± 1.78 | -14.9 ± 1.98 | -12.0 ± 1.93 | -18.8 ± 2.10 | -13.9 ± 1.95 | -13.8 ± 1.87 | -1.5 ± 2.08 |
The change in trough mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.6 ± 1.27 | -11.3 ± 1.41 | -8.9 ± 1.38 | -14.0 ± 1.50 | -9.0 ± 1.39 | -9.6 ± 1.33 | -0.3 ± 1.48 |
The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.8 ± 1.43 | -13.0 ± 1.59 | -11.6 ± 1.56 | -17.3 ± 1.67 | -13.1 ± 1.59 | -8.6 ± 1.51 | 0.7 ± 1.63 |
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -4.2 ± 0.96 | -7.7 ± 1.07 | -8.0 ± 1.05 | -10.6 ± 1.12 | -8.7 ± 1.07 | -6.0 ± 1.01 | 0.7 ± 1.09 |
The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -7.3 ± 1.56 | -11.1 ± 1.73 | -10.4 ± 1.69 | -13.1 ± 1.83 | -11.4 ± 1.72 | -10.6 ± 1.63 | 1.3 ± 1.81 |
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -4.8 ± 1.09 | -7.4 ± 1.21 | -6.8 ± 1.18 | -8.5 ± 1.29 | -7.8 ± 1.21 | -6.1 ± 1.15 | 1.9 ± 1.27 |
The change in the 24-36-hour mean systolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -9.4 ± 1.51 | -12.0 ± 1.64 | -11.5 ± 1.62 | -14.6 ± 1.72 | -13.5 ± 1.62 | -8.9 ± 1.56 | -1.4 ± 1.70 |
The change in the 24-36-hour mean diastolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -5.6 ± 1.07 | -7.9 ± 1.17 | -8.6 ± 1.15 | -9.5 ± 1.22 | -7.9 ± 1.15 | -6.5 ± 1.11 | -0.4 ± 1.21 |
The change in the 34-36-hour mean systolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -10.1 ± 1.96 | -11.2 ± 2.10 | -9.8 ± 2.15 | -13.5 ± 2.39 | -11.8 ± 2.12 | -7.4 ± 2.12 | -0.9 ± 2.17 |
The change in the 34-36-hour mean diastolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing.
| mmHg | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Change From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. | -0.4 ± 1.16 | 0.3 ± 1.26 | 0.9 ± 1.24 | 0.4 ± 1.40 | -0.6 ± 1.34 | 1.9 ± 1.35 | 2.4 ± 1.31 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azilsartan Medoxomil 5 mg QD | — | 1/65 (1.5%) | 7/65 (10.8%) |
| Azilsartan Medoxomil 10 mg QD | — | 1/64 (1.6%) | 7/64 (10.9%) |
| Azilsartan Medoxomil 20 mg QD | — | 0/64 (0%) | 13/64 (20.3%) |
| Azilsartan Medoxomil 40 mg QD | — | 1/62 (1.6%) | 8/62 (12.9%) |
| Azilsartan Medoxomil 80 mg QD | — | 0/64 (0%) | 7/64 (10.9%) |
| Olmesartan 20 mg QD | — | 1/63 (1.6%) | 7/63 (11.1%) |
| Placebo QD | — | 1/63 (1.6%) | 7/63 (11.1%) |
| Event | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| Oesophageal SpasmGastrointestinal disorders | 0/65 | 0/64 | 0/64 | 1/62 | 0/64 | 0/63 | 0/63 |
| Cardiac ArrestCardiac disorders | 0/65 | 0/64 | 0/64 | 0/62 | 0/64 | 1/63 | 0/63 |
| Hypertensive Heart DiseaseCardiac disorders | 0/65 | 0/64 | 0/64 | 0/62 | 0/64 | 1/63 | 0/63 |
| Myocardial InfarctionCardiac disorders | 0/65 | 0/64 | 0/64 | 0/62 | 0/64 | 0/63 | 1/63 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/65 | 0/64 | 0/64 | 0/62 | 0/64 | 0/63 | 1/63 |
| HeadacheNervous system disorders | 0/65 | 1/64 | 0/64 | 0/62 | 0/64 | 0/63 | 0/63 |
| HydrocephalusNervous system disorders | 0/65 | 1/64 | 0/64 | 0/62 | 0/64 | 0/63 | 0/63 |
| Wound InfectionInfections and infestations | 1/65 | 0/64 | 0/64 | 0/62 | 0/64 | 0/63 | 0/63 |
| Event | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/65 | 1/64 | 7/64 | 3/62 | 3/64 | 5/63 | 3/63 |
| NasopharyngitisInfections and infestations | 0/65 | 3/64 | 3/64 | 1/62 | 3/64 | 1/63 | 4/63 |
| DizzinessNervous system disorders | 1/65 | 3/64 | 4/64 | 2/62 | 1/64 | 1/63 | 2/63 |
| Upper respiratory tract infectionInfections and infestations | 4/65 | 0/64 | 0/64 | 2/62 | 0/64 | 0/63 | 0/63 |
| Age Categorical(participants) | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD | Total |
|---|---|---|---|---|---|---|---|---|
| <45 years | 12 | 5 | 10 | 9 | 12 | 10 | 11 | 69 |
| Between 45 and 64 years | 45 | 52 | 46 | 43 | 41 | 46 | 36 | 309 |
| ≥65 years | 8 | 6 | 8 | 10 | 11 | 7 | 14 | 64 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil 5 mg QD | Azilsartan Medoxomil 10 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Olmesartan 20 mg QD | Placebo QD | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 29 | 32 | 30 | 33 | 28 | 34 | 32 | 218 |
| Male | 36 | 31 | 34 | 29 | 36 | 29 | 29 | 224 |
The record gives a start of May 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azilsartan medoxomil